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Abstract
We extend a prior analysis on the relation between poverty and cancer incidence in a sample of
2.90 million cancers diagnosed in 16 U.S. states plus Los Angeles over the 2005-2009 period by
additionally considering stage at diagnosis. Recognizing that higher relative disparities are often
found among less-common cancer sites, our analysis incorporated both relative and absolute
measures of disparities. Fourteen of the 21 cancer sites analyzed were found to have significant
variation by stage; in each instance, diagnosis at distant stage was more likely among residents of
high-poverty areas. If the incidence rates found in the lowest-poverty areas for these 21 cancer
sites were applied to the entire country, 18,000 fewer distant-stage diagnoses per year would be
expected, a reduction of 8%. Conversely, 49,000 additional local-stage diagnoses per year would
be expected, an increase of 4%. These figures, strongly influenced by the most common sites of
prostate and female breast, speak to the trade-offs inherent in cancer screening. Integrating the
type of analysis presented here into routine cancer surveillance activities would permit a more
complete understanding of the dynamic nature of the relationship between socioeconomic status
and cancer incidence.
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Introduction
In order to better understand and ameliorate cancer disparities, it is essential to track the
relationship between cancer incidence and socioeconomic status (SES).1,2 A recent United
States-based study found that nearly all of the most common anatomic sites of cancer displayed a
significant relationship with poverty, with the rates differing by as much as a factor of two
between the poorest and most affluent groups.3 A shortcoming of this study is that it did not
consider stage at diagnosis, which itself often correlates with SES. Specifically, worse stage
distributions (that is, a tendency toward more advanced stage at diagnosis) are often
characteristic of poorer populations. To characterize a disease such as prostate cancer as
“affluent”4 is misleading because a large majority of prostate cancers are diagnosed at early
stage. Late-stage prostate cancer, in contrast, is more characteristic of poorer populations,5 but
this detail is lost when all prostate cancers are grouped together. Here we make use of the same
data set used in the recent US study to measure the role of stage in the cancer incidence-poverty
relationship.
A novel element of our analysis is that we report both absolute and relative measures of SES
disparities. Cancer sites previously identified as having the largest disparities are, in many cases,
quite rare in absolute terms (as with Kaposi sarcoma and larynx, for example), making them less
amenable to high-impact public health interventions, except insofar as they share risk factors
with more common cancer types. There have been numerous calls in recent years for the
inclusion of both absolute and relative measures in published research6-9, but these calls have not
been widely heeded: a recent review found only 7% of publications reported an absolute
measure.10
Material and Methods
We used a data file containing 2.90 million incident cancers diagnosed in 16 participating US
states (Arizona, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Iowa, Louisiana,
Minnesota, New Hampshire, New Jersey, New York, Texas, Utah, West Virginia) plus Los
Angeles County, California between 2005 and 2009.3 Together, these areas include about 42% of
the United States population for this time period and collectively have a poverty rate of 13.5%,
similar to the national average of 13.3% as measured by the American Community Survey
(ACS) during these same years. Cancer cases in the central tumor registries of these states were
geocoded to the census tract and assigned to one of four categories based on the percentage of
households below the poverty threshold as measured by the ACS: 0-<5%, 5-<10%, 10-<20%,
and over 20%. These categories have been widely used in cancer surveillance and
epidemiological research generally and have been shown to be a simple and effective measure of
SES.11-12 The 20% poverty threshold is also used as a criteria for some federal aid programs.13
The categories also conveniently divide the nation into four roughly equal parts, ranging from 22
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to 30 percent of the population. Census tracts are relatively homogeneous and stable geographic
units with an average population of about 4,000.
Using poisson regression, we modeled the cancer rate for each anatomic site of cancer by stage
for each of the four poverty categories, using a widely used list of sites developed by the
National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) program14, after
excluding those cancer sites which are not staged or rarely staged (myeloma, leukemia, and
miscellaneous sites), leaving 2.72 million tumors for analysis. We focused our analysis on the 21
most common cancer sites that collectively account for 97% of all stageable tumors. These sites
and their shorthand names used subsequently in this paper are given in Table 1. Sites less
common than these had stage-specific rates with very wide confidence intervals and were not
informative. Stage was classified using the derived SEER Summary Stage 2000 staging system
into local, regional, distant and unknown.15 The models estimated cancer rates for each site as a
function of the population size, age (5-year age groups through 85+), sex, race/ethnicity (white,
black, Hispanic, American Indian/Alaska Native, Asian and Pacific Islander), and poverty
category. The populations were obtained from a custom file developed by Woods & Poole, Inc.
for the use of the SEER program that has been described elsewhere.3,16 We additionally modeled
the cancer rates for three site groupings: all stageable sites combined, tobacco-related sites (oral,
esophagus, larynx, lung, and bladder), and HPV-related sites (penis, vagina, vulva, cervix, anus,
and the oral cancer subsites nasopharynx, oropharynx, hypopharynx, and tonsil). Breast cancer
was limited to females only; male breast cancer was included in all stageable sites combined.
The cancer counts and populations used in the models are available in an online data repository
associated with this project.17
We computed the relative risk of the highest poverty category to the lowest poverty category by
stage for each site and site grouping. In addition to this relative measure of disparity, we also
computed an absolute measure, consisting of a comparison of the total number of cases by
site/stage with the total number predicted by the model after discounting the effects of poverty
(that is, if the parameter estimates for all variables in the model for the lowest poverty category
were applied to the age, race, and sex counts and populations for the other three poverty
categories). To make this number more interpretable, we converted the counts from five-year
totals based on 42% of the US population to single-year totals based on the entire US population,
assuming that our sample was representative of the nation as a whole. That is, we took the fiveyear totals, divided by five, then divided by 0.42.

Results
The relative measure of disparity is shown in Figure 1. For clarity, only local and distant stage
are depicted here; values for all stages and sites are available in the project data repository.17 For
14 of the 21 sites (larynx, cervix, oral, lung, prostate, kidney, bladder, colorectal, female breast,
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testis, uterus, melanoma, thyroid, NHL), as well as for HPV-related, tobacco-related, and all
stageable sites combined, diagnosis at distant stage was more strongly associated with poverty
than diagnosis at early stage, as determined by the presence of non-overlapping confidence
intervals in Figure 1. For 7 sites (liver, esophagus, stomach, brain, HL, pancreas, ovary), there
was no significant difference in stage distribution by poverty. There were no sites where
diagnosis at local stage was more strongly associated with poverty.
Of the 14 sites with a stage disparity by poverty, 7 (prostate, kidney, bladder, female breast,
testis, uterus, and melanoma) had a more pronounced form, with higher-poverty areas having
both a significantly elevated risk of distant-stage diagnosis and a significantly diminished risk of
early-stage diagnosis. For example, for prostate cancer, the relative risk of diagnosis at distant
stage was 1.27 times higher in the highest poverty category than in the lowest poverty category
(95% confidence interval: 1.20-1.34), while the relative risk of early stage prostate cancer was
0.77 (0.76-0.78). This characteristic was also true of tobacco-related cancers and all cancers
combined.
The absolute measure of disparity is presented in Figure 2 (the raw counts used to develop this
figure are available in the project data repository).17 Note that the scale in the top row was
compressed by a factor of 2.5 in order to fit all sites onto a single page. The figure shows that
discounting the effects of poverty would result in large increases in the numbers of local and
regional stage prostate and breast cancers, as well as early stage bladder, melanoma, and thyroid
cancers. The only major decreases would be found among regional, distant, and unstaged lung
cancers. For most sites, the absolute changes for all stages would be small, even though they may
be large in relative terms. For example, late-stage oral cancer counts would decrease by about
1,000, barely discernable in the figure but representing a decrease of 22%.
Discounting poverty would result in an absolute reduction in cancer at local, regional, and distant
stage for seven sites (lung, colorectal, oral, liver, esophagus, cervix, larynx). For prostate, breast,
and kidney there would be a reduction in distant stage tumors but an even larger increase in the
number of local-stage tumors. For six sites, there would be an increase in local-stage tumors and
almost no change in the number of distant stage tumors (bladder, melanoma, uterus, thyroid,
brain, testis). Ovary, HL, and NHL would see an increase in tumors at all stages. Pancreas would
have small increases in regional and distant stage, and stomach would remain essentially
unchanged.
For these 21 sites combined, discounting poverty would be expected to result in nearly 46,000
additional tumors, or a 4% increase. Tumors diagnosed at early stage would increase by 64,000
(10%) and at regional stage by 3,000 (1%). Tumors diagnosed at distant stage would decrease by
18,000 (8%) and at unknown stage by 4,000 (3%).
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Discussion
We found that, in general, high poverty areas tended to have worse stage distributions than low
poverty areas. This was apparent whether the data were presented on a relative scale (Figure 1)
or absolute scale (Figure 2), though the relative scale may exaggerate the apparent importance of
poverty by presenting all cancer sites on a seemingly equal basis. If we consider only the four
most common cancer sites (prostate, breast, lung, and colorectal) that account for roughly half of
all cancers, for two of these (lung and colorectal) there would be an unqualified benefit
accompanying any reduction in poverty, as the numbers of tumors at every stage would be
expected to diminish. For the other two (breast and prostate), we would expect a tradeoff
between a modest reduction in distant-stage diagnoses and a much larger number of local-stage
diagnoses. This resembles the tradeoff seen with certain modes of cancer screening, where each
probable life saved (that is, each late-stage cancer detected earlier) must be balanced against a
larger number of lives harmed (that is, clinically insignificant early-stage cancer or pre-cancers
that need not have been detected at all).18 Notably, for the three sites most often diagnosed at
distant stage (ovary and the two lymphomas), poverty appeared to be protective. Each of these
sites are difficult to detect at an early stage, and it appears that for these sites this is true
irrespective of SES.
The generally worse stage distributions seen in areas with the highest poverty rates would be
expected to translate into higher cancer mortality rates in these areas. Unfortunately, we were not
able to measure mortality directly because geocoded vital statistics data at the national level are
not presently available at the census tract level. Even so, higher mortality rates can reasonably be
inferred from the dramatic differences in survival by stage seen for nearly all cancer sites. For
example, the 5-year relative survival for local-stage prostate cancer is at least 100% (meaning
those with this diagnosis actually tend to outlive their similarly-aged counterparts without
prostate cancer), while distant-stage is 28%.19 For breast cancer, the corresponding values are
99% and 26%, and for lung cancer, 55% and 4%.20,21 In addition, recent work by Singh et al. at
the county level found that cancer mortality in the lowest-income decile was higher than that in
the highest-income decile for all cancers combined and for lung, colorectal, prostate, breast, and
cervix.22
Cancer sites that would be expected to have more local-stage diagnoses and the same or fewer
distant-stage diagnoses after discounting poverty overlap substantially with cancer sites known
to be overdiagnosed, or detected in the absence of symptoms and unlikely or contribute to
death.23 Among these sites are prostate, breast, kidney, thyroid, and melanoma. For these sites,
the “better” stage distribution found in the most affluent group does not necessarily constitute an
advantage. For example, the rates of early-stage thyroid cancer are more than 30% higher in the
most affluent group compared with the poorest group, while the rates of distant-stage thyroid
cancer are nearly identical in both groups. To discount the effects of poverty here would only
result in an increase in the number of early (and regional) stage diagnoses. This relationship can
6

be inferred from Figure 1, as the relative risk of distant-stage thyroid cancer is close to 1, with
wide confidence intervals indicating rarity, while local-stage thyroid cancer is centered below
0.7, with narrow confidence intervals indicating it is more common. Figure 2, however, shows
the relationship much more directly.
We included unknown stage in Figure 2 as an illustration of how even a data element as
fundamental to cancer surveillance as stage is not always well-collected - often the number of
unknown stage equal or exceed the number of regional or distant stage. For most sites, the
expected change in the number of cases with unknown stage after discounting the effects of
poverty tracks the expected change in the most frequent stage. Pancreas is one exception - even
as the number of cases would increase by 5% after discounting poverty, the number with
unknown stage would decrease by 7%, suggesting the presence of a SES-based disparity in data
quality for this site.
We note that our findings are specific to the period 2005-2009, and that the dynamic nature of
cancer screening and prevention efforts and behavioral risk factors mean that the results would
not necessarily apply to the current year. For example, local-stage prostate cancer incidence in
the United States dropped by 25% between 2011 and 2012 following the United States
Preventive Services Task Force recommendation against PSA testing.24 Were we to repeat our
analysis with 2012 data, we would expect to find the projected number of additional local-stage
prostate cancer cases diagnosed after discounting poverty to diminish considerably, reducing or
perhaps even eliminating the SES disparity for local disease, while leaving the disparity for
distant disease intact. Similarly, the introduction of vaccinations against HPV-related cancers are
expected to exert substantial downward pressure on the absolute numbers of these cancers, even
as relative disparities may rise, at least temporarily, as those at greater risk for the disease may be
less likely to receive the vaccinations.25 The dynamic nature of the cancer-SES relationship
argues in favor of it becoming a routine part of national cancer surveillance rather than the
subject of an occasional focused investigation such as this one.
Overall, these findings support the general conclusion that poorer populations are more likely to
die of cancer while wealthier populations are more likely to die with it. The poor are not simply
at higher risk of more fatal cancers, but also at higher risk of being diagnosed with more fatal
forms of less-fatal cancers. Specifically, our results suggest that poverty contributes to an
additional 18,000 distant-stage cancers in the United States each year while protecting against
64,000 early-stage cancers. Reducing these disparities will require both improvements in primary
prevention and improvements in the sensitivity of cancer screening.
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Table 1. Included cancer sites.
Cancer site name14

Short name used throughout this paper

Oral cavity and pharynx

Oral

Esophagus

Esophagus

Stomach

Stomach

Colon and rectum

Colorectal

Liver and intrahepatic bile duct

Liver

Pancreas

Pancreas

Larynx

Larynx

Lung and bronchus

Lung

Melanoma of the skin

Melanoma

Breast

Breast

Cervix Uteri

Cervix

Corpus and uterus, NOS

Uterus

Ovary

Ovary

Prostate

Prostate

Testis

Testis

Urinary bladder

Bladder

Kidney and renal pelvis

Kidney

Brain and other nervous system

Brain

Thyroid

Thyroid

Hodgkin lymphoma

HL

Non-Hodgkin lymphoma

NHL
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0.5

1.0

1.5

2.0

2.5

3.0
3.2

Larynx
Cervix
HPV-related
Oral
Liver
Lung
Tobacco-related
Esophagus
Prostate
Kidney
Bladder
Colorectal
Female breast
Stomach
All stageable cancers
Testis

Distant
Local

Brain
Uterus
Melanoma
HL
Pancreas
Thyroid
Ovary
NHL

0.5

1.0

1.5

2.0

2.5

3.0

Figure 1. Relative risk of cancer incidence between highest (over 20%) and lowest (<5%)
poverty category, by site and stage, United States, 2005-2009.
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Prostate

Female Breast

Lung

Colorectal

Bladder

L R D U

L R D U

L R D U

L R D U

L R D U

NHL

Melanoma

Kidney

Uterus

Thyroid

L R D U

L R D U

L R D U

L R D U

L R D U

Pancreas

Oral

Stomach

Liver

Ovary

L R D U

L R D U

L R D U

L R D U

L R D U

Brain

Esophagus

Cervix

Larynx

HL

L R D U

L R D U

L R D U

L R D U

L R D U

150
100
50
0

50

0

50

0

50

0

Testis
50

0

All other
stageable
sites

Model using actual poverty categories
Model placing all patients into lowest poverty category
Stage at Diagnosis
L - local
R - regional
D - distant
U - unknown

L R D U

L R D U

Figure 2. Estimated number of newly diagnosed cancers per year (in thousands), by site and
stage, United States, 2005-2009, showing the influence of poverty.
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